EUVIMEDEUVIMED entdecken
Crossref

The S100A8/A9-NLRP3 inflammasome axis in HFpEF development

I Voss, K Pappritz, M Herwig, M El-Shafeey, J Oetvoes, K Kohlat, E Reynolds, A M Chitroceanu, F Edelmann, A Alogna, N Hamdani, T Vogl und 1 weitere

European Journal of Heart Failure · 12.03.2026 · 28 (Supplement_1)

DOI: 10.1093/ejhf/xuag034.050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 12.03.2026. Verfasst von I Voss und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Heart failure with preserved ejection fraction (HFpEF) develops in an outside-in mechanism where comorbidities drive systemic low-grade inflammation damaging the heart. The innate immunity member S100A8/A9 is increased in comorbidities underlying HFpEF. Though, its involvement in the pathogenesis of HFpEF has not been studied before.

Purpose

Therefore, the objective of this study was to determine the role of S100A8/A9 and its downstream signaling via the NLRP3 inflammasome in HFpEF across patients, porcine and mouse models.

Methods

Serum S100A8/A9 levels were measured in HFpEF patients and controls from the SFB 1470 HFpEF and TYPE-HF cohort, respectively. Experimental HFpEF was induced in female 13–14-months-old Göttingen mini pigs via a western diet and DOCA implant for 5 months, whereas controls received a standard diet. Blood was collected and peripheral blood mononuclear cells (PBMCs) isolated for subsequent flow cytometry analyses. The 2-hit HFpEF mouse model, induced by a high-fat diet (HFD) and L-NAME, was applied to male C57BL6 mice for 15 weeks in both wild-type (WT) and S100A9 knockout (-/-) mice. In a separate experiment, HFD+L-NAME-treated mice were administered the S100A9 inhibitor Paquinimod or vehicle during the final 4 weeks. Blood, bone marrow, spleens, adipose tissues and hearts were collected for subsequent analyses.

Results

HFpEF patients (HFA-PEFF score ≥ 5) exhibited higher S100A8/A9 serum levels compared to control patients. Female HFpEF pigs also showed elevated S100A8/A9 levels accompanied by higher percentages of S100A9+, NLRP3+ and IL-1ß+ PBMCs compared to controls. Additionally, monocyte (CD68+) and neutrophil (Ly6G+) populations were expanded in the blood. HFD+L-NAME mice depicted increased systemic and cardiac inflammation evident – among others - by elevated C-reactive protein levels and higher S100A9 protein content in the heart compared to healthy mice. Cardiac fibroblasts isolated from HFD+L-NAME WT mice had a proinflammatory phenotype by expressing more NLRP3, IL-1ß and alpha-SMA compared to fibroblasts from control WT mice. Left ventricular diastolic dysfunction was less pronounced in S100A9-/- mice subjected to HFD+L-NAME compared with their WT littermates. This improvement was accompanied by reduced cardiomyocyte passive force, restored titin phosphorylation, and decreased NLRP3+ and IL-1ß+ cells in the heart and spleen. Paquinimod treatment attenuated the abundance of NLRP3+ and IL-1ß+ cell populations in the heart and extra-cardiac organs of HFD+L-NAME mice. It also largely restored total titin and side-specific titin phosphorylation, thereby alleviating cardiomyocyte stiffness.

Conclusions

These findings support an important role of S100A8/A9 and downstream NLRP3/IL-1ß signaling in the inflammatory phenotype of HFpEF on a systemic, organ and cellular level.

Zitieren

APA

Voss, I., Pappritz, K., Herwig, M., El-Shafeey, M., Oetvoes, J., Kohlat, K., Reynolds, E., Chitroceanu, A. M., Edelmann, F., Alogna, A., Hamdani, N., Vogl, T., & Linthout, S. V. (2026). The S100A8/A9-NLRP3 inflammasome axis in HFpEF development. European Journal of Heart Failure, 28(Supplement_1). https://doi.org/10.1093/ejhf/xuag034.050

Vancouver

Voss I, Pappritz K, Herwig M, El-Shafeey M, Oetvoes J, Kohlat K, et al. The S100A8/A9-NLRP3 inflammasome axis in HFpEF development. European Journal of Heart Failure. 2026;28(Supplement_1). doi:10.1093/ejhf/xuag034.050

BibTeX
@article{Voss2026,
  author = {Voss, I and Pappritz, K and Herwig, M and El-Shafeey, M and Oetvoes, J and Kohlat, K and Reynolds, E and Chitroceanu, A M and Edelmann, F and Alogna, A and Hamdani, N and Vogl, T and Linthout, S Van},
  title = {The S100A8/A9-NLRP3 inflammasome axis in HFpEF development},
  journal = {European Journal of Heart Failure},
  year = {2026},
  volume = {28},
  number = {Supplement_1},
  doi = {10.1093/ejhf/xuag034.050}
}
Kostenlos starten →